Here, we compared the antitumoral preclinical efficacy of an intermediate dose of CD8α/4-1BB versus CD28-based anti-CAIX (G36 clone) CAR T cells providing an immune booster by releasing anti-PD-L1 antibodies against ccRCC. This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.